Article Details
Retrieved on: 2024-05-28 17:01:43
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
People randomized to the Janus kinase (JAK) inhibitor baricitinib (Olumiant) to treat COVID-19 pneumonia in a clinical trial only saw a survival ...
Article found on: www.medpagetoday.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here